yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q33404749-CEB5F7F9-7AE7-4C2F-B464-DDD8BFD2DAB7
Q33404749-CEB5F7F9-7AE7-4C2F-B464-DDD8BFD2DAB7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33404749-CEB5F7F9-7AE7-4C2F-B464-DDD8BFD2DAB7
Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (B-MuD) for the treatment of relapsed multiple myeloma.
P2860
Q33404749-CEB5F7F9-7AE7-4C2F-B464-DDD8BFD2DAB7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33404749-CEB5F7F9-7AE7-4C2F-B464-DDD8BFD2DAB7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
64a2035d63a97f4555e0f8ee3b64fc616e2a166f
P2860
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.